ID | 79183 |
著者 |
音見, 暢一
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
徳島大学 教育研究者総覧
KAKEN研究者をさがす
大塚, 秀樹
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
徳島大学 教育研究者総覧
KAKEN研究者をさがす
森田, 奈緒美
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
テラザワ, カオリ
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
フルタニ, カオリ
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
原田, 雅史
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
徳島大学 教育研究者総覧
KAKEN研究者をさがす
西谷, 弘
Department of Radiology, Institute of Health Biosciences, the University of Tokushima Graduate School
徳島大学 教育研究者総覧
KAKEN研究者をさがす
|
キーワード | GIST
Risk category
PET/CT
|
資料タイプ |
学術雑誌論文
|
抄録 | Purpose. To evaluate 18F-fluorodeoxyglucose (FDG) uptake and the pathological risk category of gastrointestinal stromal tumors (GISTs), and to investigate the possibility of determining the pathological risk category by positron emission tomography/computed tomography (PET/CT). Patients and Methods. We undertook 29 PET/CT studies in 20 patients with GISTs. Eleven of the 20 patients underwent PET/CT prior to therapy, with three of these also undergoing follow-up PET/CT after operation or imatinib therapy. Results. All eleven lesions imaged before treatment were FDG-positive on PET/CT. Seven of these eleven primary lesions were categorized as high risk and the other four primary lesions were categorized as low or intermediate risk. There was a significant difference between the maximum standardized uptake value (SUVmax) of the primary lesions categorized as high risk (11.8 3.15) and that of the primary lesions categorized as low and intermediate risk (2.88 0.47) (p 0.001). Recurrent tumors were also shown as FDG-positive. Conclusion. Primary GISTs and recurrent tumors can be detected by PET/CT. Our study suggests that the degree of FDG uptake is a useful indicator of risk category. In addition, PET/CT is probably useful for follow-up examinations of GIST after operation or imatinib therapy.
|
掲載誌名 |
The journal of medical investigation : JMI
|
ISSN | 13431420
|
cat書誌ID | AA11166929
|
巻 | 57
|
号 | 3-4
|
開始ページ | 270
|
終了ページ | 274
|
並び順 | 270
|
発行日 | 2010-08
|
備考 | The journal of medical investigation : http://medical.med.tokushima-u.ac.jp/jmi/index.html
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
部局 |
病院
医学系
|